PIN6 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXICOLATE FOR THE PRIMARY TREATMENT OF INVASIVE ASPERGILLOSIS  by Aiello, EC et al.
A155Abstracts
using data on the risk of pneumococcal disease, the serotype-
adjusted vaccine efﬁcacy, the vaccine price, decrease in the fre-
quency of adverse outcomes and quality of life for patients with
sequelae from pneumococcal disease. Due to uncertainty with
respect to herd immunity, results are presented both with and
without potential effects of herd immunity. RESULTS: Disre-
garding indirect costs, the incremental cost per QALY using 4
Prevenar doses was €96000 when herd immunity was included
and €140,000 when it was not (€57,000 and €83,000 if 3 doses
offer the same effectiveness as 4). Also accounting for indirect
costs, the numbers with 4 doses would be €37,000 and €56,000,
respectively. With the most optimistic assumptions, vaccination
would be cost saving. The vaccine price and efﬁcacy, and otitis
incidence were crucial factors in sensitivity analyses. Monte
Carlo simulations indicate that the results were robust to uncer-
tainty in other parameters. CONCLUSION: The cost-effective-
ness of pneumococcal vaccination will in particular depend on
the price of the vaccine, the efﬁcacy of the vaccine, the efﬁcacy
of three versus four vaccine shots, and the extent of herd immu-
nity. In Norway, €62,500 per QALY is the ofﬁcial cost-effec-
tiveness threshold. Vaccination can therefore be considered
cost-effective. In November 2005 the Norwegian Government
included Prevenar in the public vaccination program.
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OBJECTIVE: Invasive mycoses are associated with high mortal-
ity, therefore consuming important health care resources. Cost-
effectiveness of voriconazole vs. amphotericin B deoxycholate
(CAB) for the primary treatment of invasive aspergillosis (IA)
was evaluated using data from a randomized comparative trial
(Herbrecht, NEJM 2002), that showed the superiority of
voriconazole in terms of clinical response, survival and safety
when used as primary therapy for IA. METHODS: A model for
analytical decision was designed based on the information pro-
vided by this clinical study. Changes in the antifungal treatment
due to lack of response, as well as renal or hepatic toxicity with
the initial treatment were assessed, considering direct medical
costs only, reported in Argentine pesos. RESULTS: Average total
treatment cost in the voriconazole arm was $44,040 vs. $45,428
in the CAB arm. Using the model assumptions (efﬁcacy: 52.8%
for voriconazole, 31.6% for CAB) voriconazole was the domi-
nant treatment vs. CAB as primary therapy, with a cost per 
successfully treated patient of $83,444.96 vs. $143,858.26
respectively. One-way sensitivity analysis was performed in order
to assess the impact of relevant key variables (cost of antifun-
gals, cost of hospitalization, etc.) Even after changing these vari-
ables in a wide range, voriconazole was still cost-saving.
CONCLUSIONS: Incremental cost-effectiveness analysis indi-
cated that voriconazole was the dominant therapy due to both
lower costs and higher efﬁcacy.
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OBJECTIVES: Linezolid, the ﬁrst available oxazolidinone, has
shown efﬁcacy in the treatment of methicillin-resistant Staphy-
lococcus aureus (MRSA) infections, including nosocomial pneu-
monia. In patients with MRSA nosocomial pneumonia, survival
rate was higher for those treated with linezolid than patients
treated with vancomycin (80% versus 63.5%). Moreover, clini-
cal cure rate was superior for linezolid (59% vs 35.5%) (Chest
2003;124:1789–97). We analyzed the economic impact of these
clinical outcomes in an Argentinean setting using a decision-
analytic model. METHODS: A decision-analytic model was
developed to estimate the costs and consequences of using line-
zolid versus vancomycin in hospitalized patients with nosoco-
mial pneumonia in an Argentinean setting. Clinical and other
parameters were taken from published trials. Three Argentinean
infectologists provided data on resource utilization. For costing
purposes (tests, hospitalization, adverse events and drugs) ALFA-
BETA and IECS unit costs database were used (both are pub-
lished). Outcomes consisted of total costs per patient, cost per
death avoided, cost per life-year gained, and cost per cure.
RESULTS: According to the model results, an additional 14.3%
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